CSS
ABCL icon

Cubist Systematic Strategies’s AbCellera Biologics ABCL Stock Holding History

Cubist Systematic Strategies’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,625
Closed -$146K – 3261
2023
Q2 		$146K Sell
22,625
-53
-0.2% -$362 ﹤0.01% 2909
2023
Q1 		$171K Sell
22,678
-145,749
-87% -$1.32M ﹤0.01% 3290
2022
Q4 		$1.71M Sell
168,427
-415,554
-71% -$4.8M 0.01% 1984
2022
Q3 		$5.78M Buy
583,981
+188,649
+48% +$2.07M 0.03% 935
2022
Q2 		$4.21M Buy
395,332
+149,029
+61% +$1.26M 0.03% 1147
2022
Q1 		$2.4M Sell
246,303
-16,383
-6% -$155K 0.02% 1330
2021
Q4 		$3.76M Buy
262,686
+225,812
+612% +$3.43M 0.04% 852
2021
Q3 		$739K Sell
36,874
-223,485
-86% -$3.95M 0.01% 1755
2021
Q2 		$5.73M Buy
260,359
+221,809
+575% +$6.12M 0.06% 456
2021
Q1 		$1.31M Buy
+38,550
New +$1.54M 0.02% 1350

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Cubist Systematic Strategies's ABCL Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 22,625 shares — an estimated $146K sold.

Cubist Systematic Strategies first reported a position in ABCL in Q1 2021 and held it in 10 quarters. The position peaked at $5.78M in Q3 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 22,625 AbCellera Biologics shares in Q3 2023, an estimated $146K.
  • Cubist Systematic Strategies first reported a position in AbCellera Biologics in Q1 2021 and held it in 10 quarters.
  • Cubist Systematic Strategies's AbCellera Biologics position peaked at $5.78M in Q3 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.